GENE AND CELL THERAPIES TARGETING CNS DISORDERS MARKET ANALYSIS
Global Gene and Cell Therapies Targeting CNS Disorders Market – Regional Insights
North America is expected to expand at robust growth during the forecast period owing to increasing product approvals as well as launches. For instance, in April 2021, Biogen, a U.S. based biotechnology firm obtained clearance from China's National Medical Products Administration (NMPA) in April 2021 for its new medicine named TECFIDERA. TECFIDERA is an oral medication that is used to treat relapse multiple sclerosis.
Europe is projected to dominate the fastest CAGR in the global gene and cell therapies targeting CNS disorders market during the forecast period. Europe is estimated to contribute second largest share in the global gene and cell therapies targeting CNS disorders market owing to earlier adoption of biotechnology products in the region.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 